%0 Journal Article
%T Sarcoma of the Uterus. Guideline of the DGGG and OEGGG (S2k Level, AWMF Register Number 015/074, February 2019).
%A Denschlag D
%A Ackermann S
%A Battista MJ
%A Cremer W
%A Egerer G
%A Follmann M
%A Haas H
%A Harter P
%A Hettmer S
%A Horn LC
%A Juhasz-Boess I
%A Kast K
%A Köhler G
%A Kröncke T
%A Lindel K
%A Mallmann P
%A Meyer-Steinacker R
%A Mustea A
%A Petru E
%A Reichardt P
%A Schmidt D
%A Strauss HG
%A Tempfer C
%A Thiel F
%A Ulrich U
%A Vogl T
%A Vordermark D
%A Gass P
%A Beckmann MW
%J Geburtshilfe Frauenheilkd
%V 79
%N 10
%D Oct 2019
%M 31656317
%F 2.754
%R 10.1055/a-0882-4116
%X Aims This is an official guideline published and coordinated by the German Society of Gynecology and Obstetrics (DGGG) and the Austrian Society of Gynecology and Obstetrics (OEGGG). Because of their rarity and heterogeneous histopathology, uterine sarcomas are challenging in terms of how they should be managed clinically, and treatment requires a multidisciplinary approach. To our knowledge, there are currently no binding evidence-based recommendations for the appropriate management of this heterogeneous group of tumors. Methods This S2k guideline was first published in 2015. The update published here is the result of the consensus of a representative interdisciplinary group of experts who carried out a systematic search of the literature on uterine sarcomas in the context of the guidelines program of the DGGG, OEGGG and SGGG. Members of the participating professional societies achieved a formal consensus after a moderated structured consensus process. Recommendations The consensus-based recommendations and statements include the epidemiology, classification, staging, symptoms, general diagnostic work-up and general pathology of uterine sarcomas as well as the genetic predisposition to develop uterine sarcomas. Also included are statements on the management of leiomyosarcomas, (low and high-grade) endometrial stromal sarcomas and undifferentiated uterine sarcomas and adenosarcomas. Finally, the guideline considers the follow-up and morcellation of uterine sarcomas and the information provided to patients.